Published in Hepatitis Weekly, January 31st, 2005
According to published research from Japan, "data on 334 patients with hepatitis C virus (HCV) genotype 1b and high viral levels were extracted from two multicenter double-blind studies conducted in Japan comparing interferon (IFN) alpha-2b plus ribavirin (n=209) with IFN alpha-2b alone (n=125) for 24 weeks."
"HCV RNA assay was conducted before and 4, 12, and 24 weeks after the start and 4, 12, and 24 weeks after the end of treatment. Both sustained viral response (SVR) rate and relapse rate after the end of treatment were analyzed in relation to baseline viral levels and...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Hepatitis Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.